Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psilocybin-inspired medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin along with its own proprietary compounds.

Compass Pathfinder Ltd., a subsidiary of Compass Pathways Plc, is a British company located in Altrincham. The firm engages in research and experimental development on biotechnology.

Intima Bioscience, Inc. is an American private company located in New York, NY. The firm develops therapeutic products to treat cancer. Alessandro Riva is the CEO, in this role since 2021.\nThe company says this about itself: Intima Bioscience is a company advancing checkpoint cell therapy, an approach that combines the use of patients? own immune cells with immune checkpoint targeting, in solid tumors with curative intent. Intima is currently running a Phase 1/2 clinical study of its checkpoint cell therapy, which targets the immune checkpoint CISH in patients with gastrointestinal and colon cancers.

Pike Therapeutics specializes in developing safe and effective cannabinoid formulations with superior drug delivery. It focuses on biotech, synthetic cannabinoids, and superior patch delivery. It was founded in 2019 and headquartered in Toronto, Canada.

NeonMind Biosciences, Inc. focuses in drug development to evaluate the safety and efficacy of psychedelic substances for therapeutic uses as approved medicines. It operates through the Pharmaceutical, and Consumer divisions. The Pharmaceutical division deals with drug development of psychedelic compounds and a consumer products division with a focus on mushroom infused products including functional foods, natural health products, and dietary supplements. The Consumer divisions engages in the sale of four branded coffee products in Canada through NeonMind's direct to consumer e-commerce platform. The company was founded by Jeff B. Smith and Penny White in 2019 and is headquartered in Vancouver, Canada.

The University Hospital of Basel (German: Universitätsspital Basel, USB), in Basel, is one of the five university hospitals of Switzerland. Since 1842 it is located in a former palace, the Markgräflerhof.

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquartered in New York, NY.

Engages in the development of drug treatments and biomedical technologies including cannabis delivery technology

Mydecine Innovations Group, Inc. is a biotechnology company. It engages in the business of creating the latest novel drugs and therapies to treat mental health conditions like nicotine addiction and post-traumatic stress disorder. The company was founded by Parente Carman, Damon Michaels, and Robert Roscow on September 27, 2013 and is headquartered in Vancouver, Canada.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp's psilocybin-for-neuropsychiatric disorders, or PFN™, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders.

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Cybin IRL Ltd. is an Irish company located in North Wall Quay. The firm operates as a biopharmaceutical company. Douglas L. Drysdale is currently the CEO of the firm.

Lennham Pharmaceuticals, Inc. is an American private company located in Concord, MA. The firm develops pharmaceutical products. Bradford C. Sippy is currently the CEO of the company.\nThe company says this about itself: Lennham is a privately held, clinical-stage life sciences company focused on the creative application of deuterium chemistry to highly utilized and well-characterized compounds. Founded in 2019, Lennham’s unique approach to deuteration has enabled it to rapidly develop a pipeline of product candidates, including deuterium-enriched forms of psilocybin, caffeine, and an androgen-receptor agonist.

Terran Biosciences is an American company located in New York, NY, that engages in development of transformational therapeutics for neurological and psychiatric diseases. The firm was founded by Samuel Clark, who is the current CEO of the company.\nThe company says this about itself: Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases. Backed by a number of life-science and tech investors, Terran has built a CNS-focused, tech-enabled drug development platform, and is rapidly advancing of number of late-stage assets, which include novel psychedelic-based therapeutics.

Orthogonal Thinker is a biotech holding company, acquiring and accelerating companies engaged in DEA registered psilocybin, psychoactive compounds, clean label foods, and plant sciences. Empowering health, mental wellness and emotional intelligence through food, technology, and psychoactive compounds.

Sandoz AG, a subsidiary of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

Diamond Therapeutics, Inc. is a Canadian company located in Toronto, ON. The firm provides psychedelic drug development services. It was founded by Judy Blumstock, she is the current CEO of the firm.\nThe company says this about itself: Diamond Therapeutics is a drug development company based in Toronto, Ontario. Our mission is to develop new and better therapies for mental health conditions by unlocking the promise of psychedelic compounds. Diamond is focused on sub-perceptual, non-hallucinogenic treatments that hold potential for use across a broad patient cohort —maximizing the positive impact better drugs can have on global mental health.

Synbionik is an innovative European biotech company that designs metabolic pathways, optimizes production organisms, and optimizes production processes.

Beckley Psytech Ltd. operates as a psychedelic medicine company. It engages in helping patients suffering from neurological and mental health disorders by developing psychedelic compounds. The company was founded by Lady Amanda Feilding and Cosmo Feilding Mellen in 1998 and is headquartered in the United Kingdom.